StockData
ARS Pharmaceuticals, Inc. logo

ARS Pharmaceuticals, Inc. (SPRY) stock

SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/30
$3.89+0.08 (+2.10%)

Close on Nov 13, 2026Market cap $386.85MP/E –Yield –

ARS Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

ARS Pharmaceuticals's price to sales ratio was 3.4× on Nov 11, 2026, against 6.6× a year earlier. Over the last 2 years it ranged from 2.9× to 492.6×, with a median of 9.7×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.4×−4.7
2025Dec 31, 20258.1×−391.0
2024Dec 31, 2024399.1×−64.9
2023Apr 28, 2023464.0×–

More ARS Pharmaceuticals figures

See a number that looks wrong?